Samsung Biologics Dispute Risks Global Drug Supply, Exposes Governance Flaws

INCHEON, South Korea – March 23, 2026 – A tense labor dispute at Samsung Biologics, the world's largest contract drug manufacturer, is threatening to boil over, with its union warning of a "structural supply chain risk" that could impact pharmaceutical clients and patients worldwide. The union, representing an estimated 75% of the company's workforce, is moving to secure the legal right to strike, arguing the conflict stems not from simple wage demands but from systemic governance failures and a lack of autonomy from parent conglomerate Samsung Group.

This escalation at a linchpin of the global biopharmaceutical supply chain elevates a local labor issue into a significant international business risk. The union’s public warnings are a direct challenge to Samsung's corporate structure and its public commitments to reform its historically contentious labor relations.

A Dispute Over Governance, Not Just Wages

According to the Samsung Biologics Labor Union, the core of the problem lies in the company's inability to negotiate independently. Despite being a publicly traded entity on the KOSPI, the union alleges that critical personnel and labor relations decisions are ultimately controlled by Samsung Electronics' powerful Business Support Office. "Even if the working-level negotiators attempt to reach a compromise, final decisions are inherently influenced by the Business Support Office," stated Union President Jaesung Park. "This structural limitation fundamentally blocks autonomous agreements and prolongs the dispute."

This claim is underscored by the fact that Samsung Biologics' top HR executive is a former Samsung Electronics official who managed labor relations there. The union argues this structure is a remnant of Samsung's historical 'no-union' policy, a stance that Chairman Jae-yong Lee publicly vowed to abolish. The union contends this promise remains unfulfilled, pointing to management's "lack of experience in rational labor relations" as a direct threat to the stability required for the company's 24/7 continuous manufacturing operations.

Leaked Documents and Allegations of Unfair Practices

The union's assertions of external control and anti-union sentiment are bolstered by internal documents that were leaked in November 2025. The leak, which received significant coverage from South Korean broadcaster MBC, reportedly exposed evidence of Unfair Labor Practices (ULP) designed to suppress union activities. These documents allegedly contained sensitive employee data, including performance evaluations and plans to expand the use of lower-tier ratings for certain employees.

More critically, the leaked files suggested direct intervention by a Samsung Electronics Business Task Force in Samsung Biologics' personnel management. The materials also reportedly included logs tracking union leaders' break times and records of employees who had donated to the union, raising serious concerns about employee surveillance. Following the leak, Samsung Biologics CEO John Rim issued a public apology to employees, attributing the exposure to an "access permission error" during a system update and stating the company was conducting a legal review.

The union, however, views these events as part of a pattern of behavior. It has filed multiple legal complaints over the past year, including a criminal complaint against a senior executive for the data leak and alleged interference with union activities. Another complaint filed in September 2025 accused a Vice President of violating South Korea's Public Interest Whistleblower Protection Act by allegedly disclosing a whistleblower's identity.

Global Supply Chain on High Alert

The potential for a strike at the world's leading contract development and manufacturing organization (CDMO) has put the global pharmaceutical industry on notice. Biopharmaceutical production is a highly complex, non-stop process where any disruption can lead to the loss of entire batches of life-saving medicines, causing significant delays and financial losses. "Management's failure to resolve systemic labor disputes now poses a critical structural supply chain risk to our global biopharmaceutical clients," the union warned in a statement.

This warning comes at a time when the global drug supply chain is already under pressure from geopolitical tensions and rising costs. Pharmaceutical companies increasingly rely on a small number of large, specialized CDMOs like Samsung Biologics to produce complex biologic drugs. A shutdown, or even a slowdown, could have cascading effects, delaying clinical trials and disrupting the supply of approved medicines for cancer, autoimmune disorders, and other critical conditions. While no major client has issued a public statement, reports from as early as March 2025 indicated that global pharmaceutical partners were closely monitoring the conflict with expressed concerns over production timelines.

A Test of Samsung's ESG Commitments

The escalating conflict poses a significant challenge to Samsung Biologics' Environmental, Social, and Governance (ESG) credentials, a critical factor for its global partners. The union has explicitly framed its struggle as an effort "to establish proper ESG management and normalized corporate governance," arguing that management's actions directly violate the strict standards their clients demand. "Failing to uphold signed agreements and labor laws directly violates the strict ESG standards demanded by global pharmaceutical companies," the union stated.

This is not the first time the company's social practices have come under scrutiny. Official labor inspections in 2024 reportedly confirmed multiple violations of South Korea's Labor Standards Act. The union's current campaign, which includes filing criminal complaints against top executives for allegedly violating a collective bargaining agreement signed in December, further amplifies these ESG risks. For a company that states it is guided by international labor standards, these allegations of ULP, whistleblower retaliation, and bad-faith negotiations represent a serious contradiction that could damage its reputation and jeopardize contracts with partners who prioritize ethical and resilient supply chains.